JP2022003042A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022003042A5 JP2022003042A5 JP2021147620A JP2021147620A JP2022003042A5 JP 2022003042 A5 JP2022003042 A5 JP 2022003042A5 JP 2021147620 A JP2021147620 A JP 2021147620A JP 2021147620 A JP2021147620 A JP 2021147620A JP 2022003042 A5 JP2022003042 A5 JP 2022003042A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- pharmaceutical composition
- amd
- prevention
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023177353A JP2024016045A (ja) | 2015-10-14 | 2023-10-13 | 加齢黄斑変性のための高用量スタチン |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562241522P | 2015-10-14 | 2015-10-14 | |
| US62/241,522 | 2015-10-14 | ||
| JP2018519309A JP7037186B2 (ja) | 2015-10-14 | 2016-10-14 | 加齢黄斑変性のための高用量スタチン |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018519309A Division JP7037186B2 (ja) | 2015-10-14 | 2016-10-14 | 加齢黄斑変性のための高用量スタチン |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023177353A Division JP2024016045A (ja) | 2015-10-14 | 2023-10-13 | 加齢黄斑変性のための高用量スタチン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022003042A JP2022003042A (ja) | 2022-01-11 |
| JP2022003042A5 true JP2022003042A5 (enExample) | 2022-06-14 |
| JP7754480B2 JP7754480B2 (ja) | 2025-10-15 |
Family
ID=58517927
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018519309A Active JP7037186B2 (ja) | 2015-10-14 | 2016-10-14 | 加齢黄斑変性のための高用量スタチン |
| JP2021147620A Active JP7754480B2 (ja) | 2015-10-14 | 2021-09-10 | 加齢黄斑変性のための高用量スタチン |
| JP2023177353A Withdrawn JP2024016045A (ja) | 2015-10-14 | 2023-10-13 | 加齢黄斑変性のための高用量スタチン |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018519309A Active JP7037186B2 (ja) | 2015-10-14 | 2016-10-14 | 加齢黄斑変性のための高用量スタチン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023177353A Withdrawn JP2024016045A (ja) | 2015-10-14 | 2023-10-13 | 加齢黄斑変性のための高用量スタチン |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11331295B2 (enExample) |
| EP (1) | EP3362063B1 (enExample) |
| JP (3) | JP7037186B2 (enExample) |
| AU (1) | AU2016338540B2 (enExample) |
| CA (1) | CA3001661C (enExample) |
| DK (1) | DK3362063T3 (enExample) |
| ES (1) | ES2941347T3 (enExample) |
| FI (1) | FI3362063T3 (enExample) |
| IL (1) | IL258604B2 (enExample) |
| MX (1) | MX391944B (enExample) |
| PH (1) | PH12018500745B1 (enExample) |
| WO (1) | WO2017066529A1 (enExample) |
| ZA (1) | ZA201803097B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11789024B2 (en) | 2017-05-09 | 2023-10-17 | Massachusetts Eye And Ear Infirmary | Biomarkers for age-related macular degeneration |
| WO2019018350A1 (en) * | 2017-07-17 | 2019-01-24 | Keith Roizman | TOPICAL ADMINISTRATION OF THERAPEUTIC AGENTS COMPRISING CELL PENETRATION PEPTIDES, FOR USE IN THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND OTHER OCULAR DISEASES |
| US20200243170A1 (en) * | 2017-10-17 | 2020-07-30 | Apeliotus Technologies, Inc. | Functional biomarkers for statin therapy in age-related macular degeneration (amd) |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030065020A1 (en) * | 2001-07-13 | 2003-04-03 | Catharine Gale | Treatment of macular degeneration |
| CA2478317A1 (en) | 2002-03-04 | 2003-09-18 | Medimmune, Inc. | Methods of preventing or treating disorders by administering an integrin .alpha.v.beta.3 antagonist in combination with an hmg-coa reductase inhibitor or a bisphosphonate |
| WO2005083430A1 (en) | 2004-02-25 | 2005-09-09 | Massachusetts Eye & Ear Infirmary | Biomarkers for age-related macular degeneration (amd) |
| US7919094B2 (en) | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| WO2006083533A2 (en) * | 2005-01-14 | 2006-08-10 | The Regents Of The University Of California | Compositions and methods for inhibiting drusen formation and for diagnosing or treating drusen-related disorders |
| WO2008006535A2 (en) | 2006-07-10 | 2008-01-17 | Medigene Ag | Use of a cationic colloidal preparation for the diagnosis and treatment of ocular diseases |
| JP2008268506A (ja) * | 2007-04-19 | 2008-11-06 | Fuji Xerox Co Ltd | 現像装置、像保持体ユニットおよび画像形成装置 |
| WO2009023411A1 (en) | 2007-08-09 | 2009-02-19 | Bausch & Lomb Incorporated | Compositions and methods for treating or controlling anterior- and posterior-segment ophthalmic diseases |
| US20120156202A1 (en) | 2010-11-05 | 2012-06-21 | Shantha Totada R | Age related macular degeneration treatment |
| ES2947557T3 (es) | 2013-09-06 | 2023-08-11 | Vanda Pharmaceuticals Inc | Tratamiento de afecciones mediadas por CYR61 y VEGF |
| WO2016009430A1 (en) | 2014-07-14 | 2016-01-21 | Yeda Research And Development Co. Ltd | Reduction of aging-induced type i interferon signaling at the brain's choroid plexus or within the cns for treatment of disease or injury of the cns |
| CA2954475C (en) | 2014-07-31 | 2023-05-16 | Uab Research Foundation | Apoe mimetic peptides and higher potency to clear plasma cholesterol |
-
2016
- 2016-10-14 JP JP2018519309A patent/JP7037186B2/ja active Active
- 2016-10-14 IL IL258604A patent/IL258604B2/en unknown
- 2016-10-14 US US15/768,367 patent/US11331295B2/en active Active
- 2016-10-14 FI FIEP16856248.6T patent/FI3362063T3/fi active
- 2016-10-14 AU AU2016338540A patent/AU2016338540B2/en active Active
- 2016-10-14 EP EP16856248.6A patent/EP3362063B1/en active Active
- 2016-10-14 ES ES16856248T patent/ES2941347T3/es active Active
- 2016-10-14 DK DK16856248.6T patent/DK3362063T3/da active
- 2016-10-14 PH PH1/2018/500745A patent/PH12018500745B1/en unknown
- 2016-10-14 WO PCT/US2016/056987 patent/WO2017066529A1/en not_active Ceased
- 2016-10-14 MX MX2018004636A patent/MX391944B/es unknown
- 2016-10-14 CA CA3001661A patent/CA3001661C/en active Active
-
2018
- 2018-05-11 ZA ZA2018/03097A patent/ZA201803097B/en unknown
-
2020
- 2020-12-01 US US17/108,065 patent/US11744817B2/en active Active
-
2021
- 2021-09-10 JP JP2021147620A patent/JP7754480B2/ja active Active
-
2023
- 2023-10-13 JP JP2023177353A patent/JP2024016045A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022003042A5 (enExample) | ||
| JP6336914B2 (ja) | 脳卒中の治療のためのホルボールエステルの組成物および使用方法 | |
| JP2022177142A5 (enExample) | ||
| JP4708569B2 (ja) | 血管形成を伴う疾患の治療に対する併用 | |
| Koçer et al. | Effect of the route of administration of methylprednisolone on oedema and trismus in impacted lower third molar surgery | |
| HRP20250797T1 (hr) | Postupci za liječenje pacijenata s obiteljskom hiperkolesterolemijom | |
| KR19980701959A (ko) | 신규 제약 조합물 | |
| EP2987491B1 (en) | Orally administrable pharmaceutical composition for prevention or treatment of dry eye syndrome, comprising rebamipide or prodrug thereof | |
| US20110098314A1 (en) | Statins for the treatment of ocular hypertension and glaucoma | |
| ES2383822T3 (es) | Formulaciones para el tratamiento de anomalías de lipoproteínas que comprenden una estatina y un derivado de metilnicotinamida | |
| CN101939001B (zh) | 用于治疗卵巢癌的含有紫杉醇的组合 | |
| JP7633179B2 (ja) | 神経保護のためのカンナビノイドの組成物及び使用方法 | |
| JP2010215667A (ja) | 外網膜の疾患を処置する薬剤を製造するためのβ−アドレナリン作用受容体アンタゴニストの使用 | |
| EA009668B1 (ru) | Ifn-бета в отдельности или в комбинации с другими лекарственными средствами для лечения болезни альцгеймера и нарушений, связанных с деменцией | |
| JP2018530586A5 (enExample) | ||
| US20120208883A1 (en) | Treatment of oncological diseases | |
| JP7754480B2 (ja) | 加齢黄斑変性のための高用量スタチン | |
| US20200188405A1 (en) | Composition for treating ocular disorders such as macular degeneration, retinopathy and glaucoma | |
| JP2019518736A (ja) | 併存疾患としてアパシーを伴うアルツハイマー病の治療における使用のための５−ｈｔ６受容体アンタゴニスト | |
| EP3193900B1 (en) | Compositions based on saffron for the prevention and/or treatment of corneal dystrophies. | |
| US11590211B2 (en) | Systems for treating dermal inflammatory conditions | |
| JP4824954B2 (ja) | 口内炎治療のための口腔用組成物 | |
| CN1455679A (zh) | Melagatran用于制备治疗局部缺血症的药物的用途 | |
| KR20130137623A (ko) | 림프 부종 예방 치료제 | |
| RU2007112950A (ru) | Новые производные 3,5-секо-4-норхолестана и их применение |